Alpha 2.0
Login Register
» Authors » Shin Takusagawa

Shin Takusagawa

Explore the profile of Shin Takusagawa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 87
Followers 0
Related Specialties
Pharmacology
Biochemistry
Toxicology
Top 10 Co-Authors
Takashi Usui
Marcel van Gelderen
Takafumi Iwatsubo
Aiji Miyashita
Taiji Sawamoto
John Meijer
Virginie Kerbusch
Masako Saito
Walter Krauwinkel
Masataka Katashima
Published In
Clin Drug Investig
Xenobiotica
Clin Pharmacol Drug Dev
Drug Metab Dispos
Mol Pharm
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M Receptor-Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers
Takusagawa S, Treijtel N, Saito M, Michon I, Miyatake D, Osaki F, et al.
Clin Pharmacol Drug Dev . 2024 Aug; 13(10):1130-1142. PMID: 39120583
ASP8302 is an orally administered positive allosteric modulator of the muscarinic M receptor. Two Phase 1 studies were conducted, a first-in-human study in Europe and a Japanese phase 1 study....
2.
Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First-in-Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery
Saito M, Kojima T, Komatsu K, Takusagawa S
Clin Pharmacol Drug Dev . 2023 Dec; 13(5):454-464. PMID: 38135485
Pudexacianinium (ASP5354) chloride is an indocyanine green derivative designed to enable enhanced ureter visualization during surgery. The objective of the present analysis was to determine appropriate doses of pudexacianinium for...
3.
Pudexacianinium (ASP5354) chloride for ureter visualization in participants undergoing laparoscopic, minimally invasive colorectal surgery
Albert M, Delgado-Herrera L, Paruch J, Gerritsen-van Schieveen P, Kishimoto T, Takusagawa S, et al.
Surg Endosc . 2023 Jul; 37(9):7336-7347. PMID: 37474823
Background: Intraoperative ureteral injury, a serious complication of abdominopelvic surgeries, can be avoided through ureter visualization. Near-infrared fluorescence imaging offers real-time anatomical visualization of ureters during surgery. Pudexacianinium (ASP5354) chloride...
4.
Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β-Adrenoceptor Agonist, in Human Liver Microsomes
Konishi K, Tenmizu D, Takusagawa S
Eur J Drug Metab Pharmacokinet . 2017 Nov; 43(3):301-309. PMID: 29164523
Background And Objectives: Mirabegron is cleared by multiple mechanisms, including drug-metabolizing enzymes. One of the most important clearance pathways is direct glucuronidation. In humans, M11 (O-glucuronide), M13 (carbamoyl-glucuronide), and M14...
5.
Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects
Iitsuka H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T
Clin Ther . 2015 Mar; 37(5):1031-44. PMID: 25791612
Purpose: The objective of these studies was to evaluate the pharmacokinetic profile, safety, and tolerability of mirabegron, a β3-adrenoceptor agonist for the treatment of overactive bladder, including food effects (low-...
6.
Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies
Iitsuka H, Tokuno T, Amada Y, Matsushima H, Katashima M, Sawamoto T, et al.
Clin Drug Investig . 2013 Nov; 34(1):27-35. PMID: 24178236
Background: Mirabegron is a human β3-adrenoceptor agonist for the treatment of overactive bladder. The pharmacokinetic profile of mirabegron has been extensively characterized in healthy Caucasian subjects. Objective: The objective of...
7.
Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist
Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, et al.
Clin Drug Investig . 2013 Apr; 33(6):429-40. PMID: 23625188
Background: Mirabegron is a β3-adrenoceptor agonist for the treatment of overactive bladder. There has been little information published or presented about the involvement of cytochrome P450 (CYP) isoenzymes 3A and...
8.
Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems
Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, et al.
Mol Pharm . 2013 Apr; 10(5):1783-94. PMID: 23560393
Mirabegron, a weak-basic compound, is a potent and selective β3-adrenoceptor agonist for the treatment of overactive bladder. Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely...
9.
In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist
Takusagawa S, Miyashita A, Iwatsubo T, Usui T
Xenobiotica . 2012 Jul; 42(12):1187-96. PMID: 22834478
The potential for mirabegron, a β(3)-adrenoceptor agonist for the treatment of overactive bladder, to cause drug-drug interactions via inhibition or induction of cytochrome P450 (CYP) enzymes was investigated in vitro....
10.
Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist
Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T
Xenobiotica . 2012 Apr; 42(10):957-67. PMID: 22509825
1. Human cytochrome P450 (CYP) enzymes and esterases involved in the metabolism of mirabegron, a potent and selective human β(3)-adrenoceptor agonist intended for the treatment of overactive bladder, were identified...